

Resource Summary Report

Generated by [dkNET](#) on Aug 19, 2026

PharmMapper

RRID:SCR_022604

Type: Tool

Proper Citation

PharmMapper (RRID:SCR_022604)

Resource Information

URL: <http://lilab-ecust.cn/pharmmapper/index.html>

Proper Citation: PharmMapper (RRID:SCR_022604)

Description: Web server for potential drug target identification using pharmacophore mapping approach. Designed to identify potential target candidates for given probe small molecules including drugs, natural products, or other newly discovered compounds with binding targets unidentified using pharmacophore mapping approach. Used for potential drug target identification with comprehensive target pharmacophore database.

Synonyms: PharmMapper 2017

Resource Type: data access protocol, software resource, web service

Defining Citation: [PMID:20430828](#), [PMID:28472422](#)

Keywords: potential drug target identification, given probe small molecules, identify potential target candidates, binding targets unidentified, pharmacophore mapping approach, drug target identification, target pharmacophore database

Funding: National Natural Science Foundation of China ;
Shanghai Committee of Science and Technology ;
Major National Scientific and Technological Project of China

Availability: Free, Freely available

Resource Name: PharmMapper

Resource ID: SCR_022604

Record Creation Time: 20220802T050144+0000

Record Last Update: 20260819T044551+0000

Ratings and Alerts

No rating or validation information has been found for PharmMapper.

No alerts have been found for PharmMapper.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 220 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhuo J, et al. (2026) Decrypting potential mechanisms linking ochratoxin A to hepatocellular carcinoma: an integrated approach combining toxicology, machine learning, molecular docking, and molecular dynamics simulation. BMC pharmacology & toxicology, 27(1).

Ma X, et al. (2026) Exploration of the effect and mechanism of indirubin on infectious bovine rhinotracheitis virus based on network pharmacology. BMC veterinary research, 22(1).

Dong Y, et al. (2026) Pterostilbene Promotes Spinal Cord Injury Recovery by Inhibiting Ferroptosis via Keap1/Nrf2/SLC7A11/GPX4 Axis Activation. Antioxidants (Basel, Switzerland), 15(2).

Xu R, et al. (2026) Bisdemethoxycurcumin attenuates myocardial fibrosis in heart failure with preserved ejection fraction by targeting TGFBR1 and oxidative stress. Computational and structural biotechnology journal, 31, 422.

Huo X, et al. (2026) An integrative analysis reveals the mechanism of plastic stabilizers inducing breast cancer. PLoS computational biology, 22(3), e1014025.

Liang C, et al. (2026) Leukotriene receptor antagonists and eosinophilic granulomatosis with polyangiitis: a disproportionality analysis from FAERS, JADER, CVAR databases integrated with network pharmacology. PloS one, 21(3), e0343084.

Yang X, et al. (2026) The Small Molecule Compound Eupalinolide B Ameliorates Depressive Behaviors and Neuropathic Pain in Mice With Spared Nerve Injury: Integrating Network Pharmacology, Molecular Docking, Bioinformatics, Molecular Dynamics Simulation and Experimental Verification. CNS neuroscience & therapeutics, 32(4), e70872.

Zhong Y, et al. (2026) An integrated microbiome-drug interaction and bioinformatics approach identifies active deglycosylated and glycosidic chain metabolites of Platycodin D targeting PTPN2/HIF1A in acute lung injury. Biology direct, 21(1).

Ye Y, et al. (2026) Caffeoylquinic Acids From Lonicera japonica Thunb. as Hypoglycemic Agents: Network Pharmacology and Pharmacological Validation. Journal of diabetes

research, 2026(1), e6712215.

Wang W, et al. (2026) Integrative transcriptomic and machine learning framework reveals candidate genes and potential mechanisms of aflatoxin B1 exposure in breast cancer. *Scientific reports*, 16(1).

Bai H, et al. (2026) Pterostilbene attenuates lung ischemia-reperfusion injury: integrative insights from network pharmacology, molecular dynamics, and experimental validation. *Frontiers in pharmacology*, 17, 1747977.

Jin X, et al. (2026) Combining network pharmacology and experimental validation to study the action and mechanism of brusatol against lung adenocarcinoma. *Scientific reports*, 16(1).

Manzano JAH, et al. (2026) Dimeric Anthraquinone Rugulosin A Induces Apoptosis in Lung Adenocarcinoma and Targets PI3K/AKT/MAPK Pathways In Silico. *ACS omega*, 11(12), 18744.

He Q, et al. (2026) Repurposing trifluoperazine as a potential therapeutic agent for ovarian cancer: mechanistic insight via SRC/PI3K/AKT signaling pathway inhibition. *Journal of ovarian research*, 19(1).

Yin D, et al. (2026) Mechanism of arbutin in metabolic dysfunction-associated fatty liver disease based on multi-omics research. *Bioresources and bioprocessing*, 13(1).

Bi J, et al. (2026) Inflammation-responsive biomimetic hybrid nanovesicles reverse stem cell senescence by up-regulating SIRT1 to treat periodontitis. *Journal of nanobiotechnology*, 24(1), 176.

Gu T, et al. (2026) Salidroside ameliorates experimental autoimmune neuritis by dually modulating neuroinflammation and immune homeostasis via PI3K/AKT signaling. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 23(1), e00769.

Zhou G, et al. (2026) Using an integrative multi-omics and in vitro approach to investigate the role of tris(2-butoxyethyl) phosphate in promoting hepatic steatosis. *BMJ open gastroenterology*, 13(1).

Guo Y, et al. (2026) Association Between Organophosphate Flame Retardant Exposure and Trouble Sleeping: Integrating Epidemiological Evidence with Mechanistic Insights. *International journal of molecular sciences*, 27(4).

Luo Y, et al. (2026) Multi-scale evidence chain: Linking environmental BPA exposure to ovarian cancer through integrated omics and experimental models. *Translational oncology*, 69, 102791.